Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography.
A fast and reliable method has been established for the determination of the dopamine D-1 receptor antagonist (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1 H-3- benzazepin-7-ol (NNC 01-0687) in plasma. A combination of reversed-phase extraction on C18 columns and straight-phase high-performance liquid chromatographic analysis with ultraviolet detection at 287 nm resulted in very clean chromatograms. The limit of quantitation was about 1 ng/ml of plasma. Validation of the method showed good selectivity, linearity, recovery, accuracy and precision. Several modifications of the method were possible with little or no influence on the assay.
Christensen
J V
JV
Department of Pharmacokinetics, Novo Nordisk A/S, Måløv, Denmark.
D001552:Benzazepines / Q000097:blood*; D001572:Benzofurans / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors*; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D001552:Benzazepines; D001572:Benzofurans; D017447:Receptors, Dopamine D1; C077122:5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol